Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

AbbVie Hopes Imbruvica, Marivet Build Momentum Before Humira Downturn

Jul 28 2017

• By Joseph Haas

Bottles

Related Content

Gilead Raises HCV Guidance Slightly, Still Mum On M&A

Jul 26 2017

Humira's Inevitable Decline: What's Waiting In The Wings?

Mar 08 2017

AbbVie Next-Gen Combo Data Further Goal To Target Hard-To-Cure HCV Patients

Apr 20 2017

Imbruvica Leads Sea Change In CLL Landscape

Mar 14 2016

Gilead Offers Split Guidance For HCV; Expects Further Decline In 2017

Feb 08 2017

AbbVie's New Hep C Drug Will Break Gilead's Dominance If Approved In EU

Jun 21 2017

Related Companies

AbbVie Inc.

Johnson & Johnson

Gilead Sciences, Inc.

Additional Topics

Sales & Earnings Launches Business Strategies Commercial BioPharmaceutical

More from Earnings

More from Business

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window